{"id": "644ea20157b1c7a31500007a_0", "question": "What are the outcomes of ubiquitination?", "context": "Ubiquitination is a post-translational modification that generally directs proteins for degradation by the proteasome or by lysosomes. However, ubiquitination has been implicated in many other cellular processes, including transcriptional regulation, DNA repair, regulation of protein-protein interactions and association with ubiquitin-binding scaffolds.", "label": "yes"}
{"id": "644ea20157b1c7a31500007a_1", "question": "What are the outcomes of ubiquitination?", "context": "Ubiquitin is best known for its function in targeting proteins for degradation by the proteasome. Recent studies have revealed several new functions of ubiquitin that are independent of proteasomal degradation. These functions include the novel signaling roles of ubiquitin in DNA repair and the activation of protein kinases such as IkappaB kinase.", "label": "yes"}
{"id": "644ea20157b1c7a31500007a_2", "question": "What are the outcomes of ubiquitination?", "context": "Ubiquitination ofendogenous proteins is one of the key regulatory steps that guides protein degradation through regulation of proteasome activity.", "label": "yes"}
{"id": "6440306357b1c7a315000046_0", "question": "What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients?", "context": "To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich's ataxia patients", "label": "yes"}
{"id": "6440306357b1c7a315000046_1", "question": "What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients?", "context": "The primary endpoints were safety, tolerability, and pharmacokinetic analysis. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_0", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Serpentine supravenous hyperpigmentation (SSH) is a unique type of chemotherapy-associated drug eruption, characterized by hyperpigmentation along the superficial venous network.", "label": "yes"}
{"id": "63eee73ef36125a426000003_1", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Serpentine supravenous hyperpigmentation (SSH) is a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-FU1-3, but also seen with docetaxel4,5, fotemustine6, and vinorelbine7. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_2", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_3", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Serpentine erythematous or hyperpigmented streaks along the superficial venous network proximal to the site of injection may occur as a distinctive eruption after infusion of several chemotherapeutic agents. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_4", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Serpentine supravenous hyperpigmentation was the term coined by Hrushesky to describe increased pigmentation of the skin immediately overlying the venous network used for intravenous infusion of 5-fluorouracil. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_5", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "Two cases of serpentine supravenous hyperpigmentation developing in the area of fotemustine infusions are reported. ", "label": "yes"}
{"id": "63eee73ef36125a426000003_6", "question": "What causes Serpentine Supravenous Hyperpigmentation?", "context": "The serpentine supravenous hyperpigmentation on the lower extremities was uniform in width and color, which contrasts with the darker discoloration near the site of infusion seen with PSSH associated with chemotherapy.", "label": "yes"}
{"id": "644f0ca257b1c7a315000089_0", "question": "What are the hallmarks of cancer?", "context": "The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction.", "label": "yes"}
{"id": "6446838957b1c7a31500006e_0", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder clinically characterized by slowly progressive weakness affecting humero-peroneal muscles, early joint contractures and cardiomyopathy with conduction defects. Autosomal dominant and recessive forms are caused by mutations in lamin A/C gene.", "label": "yes"}
{"id": "6446838957b1c7a31500006e_1", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "X-linked recessive form of EDMD is caused by mutation in EMD (or STA) gene ", "label": "yes"}
{"id": "6446838957b1c7a31500006e_2", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "The LINC components emerin, lamin A/C, SUN1, SUN2, nesprin-1 and nesprin-2 interact with each other at the NE and also with other binding partners including actin filaments and B-type lamins.", "label": "yes"}
{"id": "6446838957b1c7a31500006e_3", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "Emerin was the first LINC component associated with a human disease, namely EDMD (Emery-Dreifuss muscular dystrophy).", "label": "yes"}
{"id": "6446838957b1c7a31500006e_4", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "Later on, other components of the LINC complex, such as lamins A/C and small isoforms of nesprin-1 and nesprin-2, were found to be associated with EDMD", "label": "yes"}
{"id": "6446838957b1c7a31500006e_5", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "Only approximately 46% of the EDMD patients can be linked to genes of LINC and non-LINC components, pointing to further genes involved in the pathology of EDMD", "label": "yes"}
{"id": "6446838957b1c7a31500006e_6", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": " Recently, screening of binding partners of LINC components as candidates identified LUMA (TMEM43), encoding a binding partner of emerin and lamins, as a gene involved in atypical EDMD.", "label": "yes"}
{"id": "6446838957b1c7a31500006e_7", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": " EDMD-causing mutations in STA/EMD (encoding emerin", "label": "yes"}
{"id": "6446838957b1c7a31500006e_8", "question": "Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?", "context": "Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications. EDMD classically presents with muscle weakness, early contractures, cardiac conduction abnormalities and cardiomyopathy, although the presence and severity of these manifestations vary by subtype and individual. Associated genes include EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43, SUN1, SUN2, and TTN, encoding emerin, lamin A/C, nesprin-1, nesprin-2, FHL1, LUMA, SUN1, SUN2, and titin, respectively.", "label": "yes"}
{"id": "642f49db57b1c7a315000014_0", "question": "List the luciferase substrates", "context": "new firefly bioluminescence substrates, and further evaluated their activities in vitro and in vivo. It is worth noting that the maximum biological emission wavelength of novel luciferin analogue AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) is 100 nm red-shifted compared with D-luciferin, ", "label": "yes"}
{"id": "642f49db57b1c7a315000014_1", "question": "List the luciferase substrates", "context": "AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) ", "label": "yes"}
{"id": "642f49db57b1c7a315000014_2", "question": "List the luciferase substrates", "context": "The new substrate AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) showed better bioluminescence performance in vivo.", "label": "yes"}
{"id": "642f49db57b1c7a315000014_3", "question": "List the luciferase substrates", "context": "The interaction of luciferases from two types of luminous bacteria, Photobacterium leiognathi and Vibrio harveyi, with their substrates [the photorecovered FMNH2 and long-chain aldehydes--decanal (C10), dodecanal (C12) and tetradecanal (C14)] ", "label": "yes"}
{"id": "642f49db57b1c7a315000014_4", "question": "List the luciferase substrates", "context": "Following coadministration of two luciferase substrates, native coelenterazine and luciferin,", "label": "yes"}
{"id": "642f49db57b1c7a315000014_5", "question": "List the luciferase substrates", "context": "Comparisons of experimental data with predictions based upon the three inhibitory models show that product inhibition during luciferase luminescence is noncompetitive with respect to both luciferin and ATP as substrates.", "label": "yes"}
{"id": "6450bf2557b1c7a31500008d_0", "question": "Which are the known inflammatory myopathies?", "context": "Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases.", "label": "yes"}
{"id": "6450bf2557b1c7a31500008d_1", "question": "Which are the known inflammatory myopathies?", "context": "This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS).", "label": "yes"}
{"id": "6450bf2557b1c7a31500008d_2", "question": "Which are the known inflammatory myopathies?", "context": "The search strategy from the 2021 Cochrane Physical Activity review in neuromuscular disease was used, and we selected articles that included people with IIM, including Dermatomyositis (DM), Inclusion Body Myositis (IBM), Immune Mediated Necrotising Myopathy (IMNM) [also known as necrotizing autoimmune myopathy (NAM)], and Polymyositis (PM).", "label": "yes"}
{"id": "64041260201352f04a000013_0", "question": "What are features of the The Trauma Triad of Death?", "context": "It is a serious threat to prehospital patients and especially injured patients, since it can induce a vicious cycle of the synergistic effects of hypothermia, acidosis and coagulopathy; referred to as the trauma triad of death. ", "label": "yes"}
{"id": "64041260201352f04a000013_1", "question": "What are features of the The Trauma Triad of Death?", "context": "The trauma triad of death: hypothermia, acidosis, and coagulopathy.", "label": "yes"}
{"id": "64041260201352f04a000013_2", "question": "What are features of the The Trauma Triad of Death?", "context": "The \"new\" golden hour may well be the time in the operating room before the patient reaches the physiologic limit, defined as the onset of the triad: hypothermia, acidosis and coagulopathy.", "label": "yes"}
{"id": "644eb55457b1c7a315000081_0", "question": "What are some examples of epigenetic modifications?", "context": "Epigenetic modifications may constitute changes in DNA methylation, histone modifications (methylation, acetylation etc), and changes in non-coding RNA, leading to an altered gene expression profile.", "label": "yes"}
{"id": "644eb55457b1c7a315000081_1", "question": "What are some examples of epigenetic modifications?", "context": "Epigenetic modifications viz. DNA methylation, histone modifications, and RNA-based alterations play a crucial role in the development of cardiovascular diseases.", "label": "yes"}
{"id": "644eb55457b1c7a315000081_2", "question": "What are some examples of epigenetic modifications?", "context": "Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs.", "label": "yes"}
{"id": "644eb55457b1c7a315000081_3", "question": "What are some examples of epigenetic modifications?", "context": "Eukaryotic gene expression is regulated not only by genomic enhancers and promoters, but also by covalent modifications added to both chromatin and RNAs. Whereas cellular gene expression may be either enhanced or inhibited by specific epigenetic modifications deposited on histones (in particular, histone H3), these epigenetic modifications can also repress viral gene expression, potentially functioning as a potent antiviral innate immune response in DNA virus-infected cells.", "label": "yes"}
{"id": "6450f02257b1c7a315000091_0", "question": "Which are the types of Friedreich's Ataxia based on onset age?", "context": "Friedreich's ataxia is classically considered a disease with onset in the first or second decade. However, late-onset (age of onset 25-39 years) and very-late-onset (age of onset >40 years) forms do occur rarely.", "label": "yes"}
{"id": "6402bd7c201352f04a000006_0", "question": "Which drugs were tested in the FAKTION trial?", "context": "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.", "label": "yes"}
{"id": "6402bd7c201352f04a000006_1", "question": "Which drugs were tested in the FAKTION trial?", "context": "INTERPRETATION: Updated FAKTION data showed that capivasertib addition to fulvestrant extends the survival of participants with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer. ", "label": "yes"}
{"id": "6402bd7c201352f04a000006_2", "question": "Which drugs were tested in the FAKTION trial?", "context": "Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. ", "label": "yes"}
{"id": "6402bd7c201352f04a000006_3", "question": "Which drugs were tested in the FAKTION trial?", "context": "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.", "label": "yes"}
{"id": "6402bd7c201352f04a000006_4", "question": "Which drugs were tested in the FAKTION trial?", "context": "The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.", "label": "yes"}
{"id": "644ea41957b1c7a31500007b_0", "question": "What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?", "context": "RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons. The combination of inclusion and exclusion of introns and exons in pre-mRNA can generate vast diversity in mature mRNA from a limited number of genes.", "label": "yes"}
{"id": "644ea41957b1c7a31500007b_1", "question": "What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?", "context": "Transport of messenger RNA (mRNA) from the nucleus to the cytoplasm is an essential step of eukaryotic gene expression. In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5' ends, splicing and cleavage/polyadenylation at the 3' ends.", "label": "yes"}
{"id": "644ea41957b1c7a31500007b_2", "question": "What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?", "context": "Messenger RNA precursors (pre-mRNAs) are produced as the nascent transcripts of RNA polymerase II (Pol II) in eukaryotes and must undergo extensive maturational processing, including 5'-end capping, splicing, and 3'-end cleavage and polyadenylation.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_0", "question": "What are the types of Spinal Muscular Atrophy?", "context": "SMA with a clinical diagnosis of SMA types 1, 2, or 3", "label": "yes"}
{"id": "64463a5057b1c7a315000064_1", "question": "What are the types of Spinal Muscular Atrophy?", "context": " In phase 2/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type 1 and in patients aged 2-25 years with SMA types 2 or 3.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_2", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Adulthood-onset SMA (SMA type 4) is rare, with few isolated cases reported.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_3", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Twenty patients with SMA type 4 were identified in a Brazilian cohort of 227 patients with SMA. ", "label": "yes"}
{"id": "64463a5057b1c7a315000064_4", "question": "What are the types of Spinal Muscular Atrophy?", "context": "This study represents the largest cohort of patients with SMA type 4 and provides functional, genetic, radiological and neurophysiological features ", "label": "yes"}
{"id": "64463a5057b1c7a315000064_5", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Adolescent and adult patients with SMA types 3 and 4", "label": "yes"}
{"id": "64463a5057b1c7a315000064_6", "question": "What are the types of Spinal Muscular Atrophy?", "context": "We found no evidence for the contribution of motor unit and capillary recruitment capacity of the upper arm muscles in adolescent and adult patients with SMA types 3 and 4 as primary limiting factors to premature fatigue during execution of a maximal arm-cycling task.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_7", "question": "What are the types of Spinal Muscular Atrophy?", "context": "We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_8", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. ", "label": "yes"}
{"id": "64463a5057b1c7a315000064_9", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12-40)years were treated with nusinersen for 3.55 (1.78-4.53)years.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_10", "question": "What are the types of Spinal Muscular Atrophy?", "context": "On October 1st, 666 patients have been enrolled (357 children and 309 adults) by 44 out of 51 open centers of the national network (FILNEMUS) with: 150 type 1 (22%); 278 type 2 (42%), 232 type 3 (35%) and 4 type 4 (1%) respectively.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_11", "question": "What are the types of Spinal Muscular Atrophy?", "context": "The identification of the underlying gene defects for familial ALS, spinal muscular atrophy (SMA), and spinal muscular atrophy with respiratory distress (SMARD) has pointed to distinct pathophysiological mechanisms that are responsible for the various forms of the disease. ", "label": "yes"}
{"id": "64463a5057b1c7a315000064_12", "question": "What are the types of Spinal Muscular Atrophy?", "context": "Interestingly, UBA1 mutations can also cause infantile-onset X-linked spinal muscular atrophy (XL-SMA).", "label": "yes"}
{"id": "64463a5057b1c7a315000064_13", "question": "What are the types of Spinal Muscular Atrophy?", "context": "The mutation identified here and the XL-SMA causative mutations were shown to affect amino acids positioned in the vicinity of UBA1's ATP binding site and to cause structural changes.", "label": "yes"}
{"id": "64463a5057b1c7a315000064_14", "question": "What are the types of Spinal Muscular Atrophy?", "context": "The contribution of this same gene to the etiology of XL-SMA is discussed.", "label": "yes"}
{"id": "64041355201352f04a000014_0", "question": "What are features of the Mackler\u2019s Triad?", "context": "Most commonly affecting males between 50 and 70 years of age, Clinically, the Mackler triad is vomiting, severe chest pain, and subcutaneous cervical emphysema.", "label": "yes"}
{"id": "6446ac0b57b1c7a315000072_0", "question": "Which are the motor neuron diseases?", "context": "Motor neurons (MNs) are specialized neurons responsible for muscle contraction that specifically degenerate in motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). ", "label": "yes"}
{"id": "6446ac0b57b1c7a315000072_1", "question": "Which are the motor neuron diseases?", "context": "Spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), hereditary spastic paraplegia (HSP), and amyotrophic lateral sclerosis (ALS) are all MNDs", "label": "yes"}
{"id": "6446ac0b57b1c7a315000072_2", "question": "Which are the motor neuron diseases?", "context": "Amyotrophic Lateral Sclerosis (ALS), Spinal Bulbar Muscular Atrophy (SBMA), and Spinal Muscular Atrophy (SMA) are motor neuron diseases (MNDs) characterised by progressive motor neuron degeneration, weakness and muscular atrophy.", "label": "yes"}
{"id": "641dc49b690f196b51000042_0", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartmen", "label": "yes"}
{"id": "641dc49b690f196b51000042_1", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.", "label": "yes"}
{"id": "641dc49b690f196b51000042_2", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1)", "label": "yes"}
{"id": "641dc49b690f196b51000042_3", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Fulminant Hepatic Failure in Dengue Fever Without Plasma Leakage: A Case Report", "label": "yes"}
{"id": "641dc49b690f196b51000042_4", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock", "label": "yes"}
{"id": "641dc49b690f196b51000042_5", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock.", "label": "yes"}
{"id": "641dc49b690f196b51000042_6", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE).", "label": "yes"}
{"id": "641dc49b690f196b51000042_7", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A", "label": "yes"}
{"id": "641dc49b690f196b51000042_8", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Background: Cytokine release syndrome (CRS) significantly contributes to the pathophysiology and progression of COVID-19. It is speculated that therapeutic plasma exchange (TPE) can dampen CRS via elimination of pathogenic cytokines.", "label": "yes"}
{"id": "641dc49b690f196b51000042_9", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Successful therapeutic plasma exchange in a case with extremely severe hypertriglyceridemia secondary to diabetic ketoacidosis concomitant with type IX glycogen storage diseas", "label": "yes"}
{"id": "641dc49b690f196b51000042_10", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Therapeutic plasma exchange (TPE) is a treatment option to reduce thyroid hormones", "label": "yes"}
{"id": "641dc49b690f196b51000042_11", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "herapeutic plasma exchange in hyperthyroidism prior to surgery", "label": "yes"}
{"id": "641dc49b690f196b51000042_12", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.", "label": "yes"}
{"id": "641dc49b690f196b51000042_13", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option", "label": "yes"}
{"id": "641dc49b690f196b51000042_14", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": " We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. ", "label": "yes"}
{"id": "641dc49b690f196b51000042_15", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Total Plasma Exchange in Neuromuscular Junction Disorders-", "label": "yes"}
{"id": "641dc49b690f196b51000042_16", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Total plasma exchange (TPE) has proven efficacy in NJD", "label": "yes"}
{"id": "641dc49b690f196b51000042_17", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.", "label": "yes"}
{"id": "641dc49b690f196b51000042_18", "question": "Treatment with plasma exchange (TPE) is used for what diseases", "context": "Therapeutic plasma exchange (TPE) and immunoadsorption (IA) are first or second line treatment options in patients with neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMSOD), chronic inflammatory demyelinating polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome), and autoimmune encephalitis", "label": "yes"}
{"id": "6451034c57b1c7a315000095_0", "question": "How is Leigh syndrome inherited?", "context": "LS is a rare progressive multisystem fatal disorder inherited by autosomal recessive, X-linked and maternal transmission. ", "label": "yes"}
{"id": "6451034c57b1c7a315000095_1", "question": "How is Leigh syndrome inherited?", "context": "LS is due to a deficit of various respiratory chain and Krebs cycle enzymes resulting in insufficient production of adenosine triphosphate (ATP), in particular cytochrome-c-oxidase (COX), pyruvate carboxylase, pyruvate dehydrogenase complex and complex I of the respiratory chain, which share an autosomal recessive and X-linked mode of transmission. Cases with maternal inheritance (MILS) are due to a mitochondrial DNA (mtDNA) point mutation.", "label": "yes"}
{"id": "61f901bd882a024a10000047_0", "question": "List features of the Zinner syndrome.", "context": "Zinner syndrome comprises triad of seminal vesicle cyst, unilateral renal agenesis and ipsilateral ejaculatory duct obstruction. ", "label": "yes"}
{"id": "61f901bd882a024a10000047_1", "question": "List features of the Zinner syndrome.", "context": "We present the case of a 51-year-old male with Zinner syndrome, which is a rare disease, resulting from an abnormal evolution of the mesonephric (Wolffian) duct. It consists in cystic dilations of one seminal vesicle and/or ejaculatory duct and ipsilateral renal agenesis.", "label": "yes"}
{"id": "61f901bd882a024a10000047_2", "question": "List features of the Zinner syndrome.", "context": "A rare triad of Wolffian duct anomaly known as Zinner syndrome includes unilateral renal agenesis with ipsilateral seminal vesicle cyst and ejaculatory duct obstruction.", "label": "yes"}
{"id": "61f901bd882a024a10000047_3", "question": "List features of the Zinner syndrome.", "context": "Zinner syndrome, first described in 1914, refers to a triad of features consisting of seminal vesicle cysts, ejaculatory duct obstruction, and unilateral (mostly ipsilateral) renal agenesis. ", "label": "yes"}
{"id": "61f901bd882a024a10000047_4", "question": "List features of the Zinner syndrome.", "context": "The triad of SV cysts, ipsilateral renal agenesis and ejaculatory duct obstruction is known as the Zinner syndrome.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_0", "question": "What factors are associated with severe COVID-19?", "context": " There was low or moderate certainty evidence for a large (\u22652-fold) magnitude of association between hospitalisation in people with COVID-19, and: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age >45 years, male gender, black race/ethnicity (vs non-Hispanic white), homelessness and low income. Age >60 and >70 years may be associated with large increases in mechanical ventilation and severe disease, respectively. For mortality, a large magnitude of association may exist with liver disease, Bangladeshi ethnicity (vs British white), age >45 years, age >80 years (vs 65-69 years) and male gender among 20-64 years (but not older). Associations with hospitalisation and mortality may be very large (\u22655-fold) for those aged \u226560 years.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_1", "question": "What factors are associated with severe COVID-19?", "context": "Increasing age (especially >60 years) may be the most important risk factor for severe outcomes.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_2", "question": "What factors are associated with severe COVID-19?", "context": "In multivariable logistic regression analyses, increasing age (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 1.1-1.2, p<0.001), male gender (aOR 1.8, 95% CI 1.2-2.7, p = 0.002), Hispanic ethnicity (aOR 1.9, 95% CI 1.2-3.1, p = 0.01), obesity (3.1, 95% CI 1.9-5.1, p<0.001), asthma history (aOR 2.3, 95% CI 1.3-4.0, p = 0.003), congestive heart failure (aOR 6.0, 95% CI 1.5-25.1, p = 0.01), cerebrovascular disease (aOR 4.9, 95% CI 1.7-14.7, p = 0.004), and diabetes (aOR 3.4, 95% CI 1.9-6.2, p<0.001) were predictive of severe disease diagnoses within 30 days.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_3", "question": "What factors are associated with severe COVID-19?", "context": "The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_4", "question": "What factors are associated with severe COVID-19?", "context": "Factors associated with severe COVID-19 were older age [adjusted relative risk (aRR) 1.78, 95% confidence interval (CI) 1.61-1.97; P < 0.0001], diabetes (aRR 2.00, 95% CI 1.20-3.32; P = 0.007), cardiovascular disease (aRR 2.53, 95% CI 1.53-4.17; P < 0.0001), malignancy (aRR 4.57, 95% CI 1.62-12.87; P = 0.004), surgery/trauma (aRR 23.98, 95% CI 10.35-55.57; P < 0.0001) and human immunodeficiency virus infection (aRR 4.24, 95% CI 1.55-11.61; P = 005).", "label": "yes"}
{"id": "643df77457b1c7a31500003b_5", "question": "What factors are associated with severe COVID-19?", "context": "Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13).", "label": "yes"}
{"id": "643df77457b1c7a31500003b_6", "question": "What factors are associated with severe COVID-19?", "context": "Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_7", "question": "What factors are associated with severe COVID-19?", "context": "Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_8", "question": "What factors are associated with severe COVID-19?", "context": " Older age, male sex, non-White race, Hispanic ethnicity, obesity, and a higher number of chronic conditions were associated with increased risk of severe infection.", "label": "yes"}
{"id": "643df77457b1c7a31500003b_9", "question": "What factors are associated with severe COVID-19?", "context": "In particular, persons 0 to 44 years of age with cancer, chronic neurologic disorders, hematologic disorders, ischemic heart disease, and other endocrine disorders had a greater than 3-fold increased risk of severe infection compared with persons of the same age without those conditions.", "label": "yes"}
{"id": "6441371857b1c7a315000057_0", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": " Non-pharmacological comfort measures such as breastfeeding, swaddling and sweet solutions are inconsistently implemented and are not always practical or effective in reducing the transmission of noxious input to the brain. ", "label": "yes"}
{"id": "6441371857b1c7a315000057_1", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "In this comparative effectiveness research 195 neonates >36 weeks' gestation were randomised to three groups, receiving during heel stick: (i) breastfeeding, (ii) sucrose 24% liquid with non-nutritive sucking and (iii) sucrose 24% gel with non-nutritive sucking. ", "label": "yes"}
{"id": "6441371857b1c7a315000057_2", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "All the methods analysed has shown to be effective in reducing pain", "label": "yes"}
{"id": "6441371857b1c7a315000057_3", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "There was an increase in odds of pain following liquid sucrose compared to breastfeeding (OR = 1.60; 95% CI: 0.82-3.3; p = 0.17).", "label": "yes"}
{"id": "6441371857b1c7a315000057_4", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "Sucrose 24% gel with non-nutritive sucking seems to be a valid alternative when breastfeeding is not possible. Further research is needed.", "label": "yes"}
{"id": "6441371857b1c7a315000057_5", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "Oral sucrose is commonly given to children to reduce procedural pain.", "label": "yes"}
{"id": "6441371857b1c7a315000057_6", "question": "What are the currently used non-pharmacological measures for the management of procedural pain in neonates?", "context": "he present systematic review and meta-analyses demonstrate that glucose reduces pain scores and crying during single heel lances and venipunctures. Results indicate that 20% to 30% glucose solutions have analgesic effects and can be recommended as an alternative to sucrose for procedural pain reduction in healthy term and preterm neonates.", "label": "yes"}
{"id": "6442810c57b1c7a31500005a_0", "question": "Which are the types of Facioscapulohumeral Muscular Dystrophy?", "context": " The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4), in the presence of a specific 4qA161 phenotype. ", "label": "yes"}
{"id": "644f057357b1c7a315000087_0", "question": "Which transcription factors are essential for the melanocyte lineage?", "context": "Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage.", "label": "yes"}
{"id": "644f057357b1c7a315000087_1", "question": "Which transcription factors are essential for the melanocyte lineage?", "context": "MITF and SOX10 actively recruit BRG1 to a set of MITF-associated regulatory elements (MAREs) at active enhancers. Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.", "label": "yes"}
{"id": "644f057357b1c7a315000087_2", "question": "Which transcription factors are essential for the melanocyte lineage?", "context": "MITF governs multiple steps in the development of melanocytes, including specification from neural crest, growth, survival, and terminal differentiation.", "label": "yes"}
{"id": "644f057357b1c7a315000087_3", "question": "Which transcription factors are essential for the melanocyte lineage?", "context": "However, MITF does not act alone.", "label": "yes"}
{"id": "644f057357b1c7a315000087_4", "question": "Which transcription factors are essential for the melanocyte lineage?", "context": "ChIP-seq studies have indicated that the transcription factors SOX10, YY1, and TFAP2A co-occupy subsets of regulatory elements bound by MITF in melanocytes. Analyses at single loci also support roles for LEF1, RB1, IRF4, and PAX3 acting in combination with MITF, while sequence motif analyses suggest that additional transcription factors colocalize with MITF at many melanocyte-specific regulatory elements. However, the precise biochemical functions of each of these MITF collaborators and their contributions to gene expression remain to be elucidated.", "label": "yes"}
{"id": "6417921b690f196b51000033_0", "question": "What are common symptoms in female carriers of DMD?", "context": "8% of female DMD carriers have muscle weakness and cardiomyopathy. ", "label": "yes"}
{"id": "6417921b690f196b51000033_1", "question": "What are common symptoms in female carriers of DMD?", "context": "Pseudohypertrophy of calf muscles, muscular weakness, compensatory movements and longer timed performance on functional tasks were observed in most of the cases. ", "label": "yes"}
{"id": "6417921b690f196b51000033_2", "question": "What are common symptoms in female carriers of DMD?", "context": "Clinical manifestation of asymmetrical muscle weakness and compensatory movements, or both can be found in female carriers of DMD mutations, which can adversely affect posture and functional performance of these patients.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_0", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inheritance pattern, age of onset and whether the primary defect results in an abnormality of the myelin or axon of the nerve.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_1", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2)", "label": "yes"}
{"id": "6446caac57b1c7a315000074_2", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": " CMT1, or hypertrophic form in which mutations or a duplication were found on chromosome 17 is the most frequent (CMT1A), CMT2 is the neuronal form, CMT3 is termed the Dejerine-Sottas disease, CMT4 recessive forms, CMT5 a form with associated pyramidal features, and CMTX. ", "label": "yes"}
{"id": "6446caac57b1c7a315000074_3", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. ", "label": "yes"}
{"id": "6446caac57b1c7a315000074_4", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "The subdivision into demyelinating CMT1 and axonal CMT2 types was a milestone and is still valid for the majority of patients.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_5", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "Intermediate conduction velocities are often found in males with X-linked CMT (CMTX), and different intermediate CMT types have been identified", "label": "yes"}
{"id": "6446caac57b1c7a315000074_6", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_7", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_8", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "Mutations of the gene encoding mitofusin 2 (MFN2) have recently been identified as the cause of approximately one-third of dominantly inherited cases of the axonal degenerative forms of Charcot-Marie-Tooth disease (CMT type 2A) and of rarer variants.", "label": "yes"}
{"id": "6446caac57b1c7a315000074_9", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "The latter include a severe, early-onset axonal neuropathy, which may occur in autosomal dominant or recessive forms, as well as some instances associated with pyramidal tract involvement (CMT type 5),", "label": "yes"}
{"id": "6446caac57b1c7a315000074_10", "question": "Which are the types of Charcot-Marie-Tooth Disease (CMT)?", "context": "with optic atrophy (CMT type 6),", "label": "yes"}
